<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://www.mynewsdesk.com/dk/rss/source/833/pressrelease"/>
    <title>Bristol-Myers Squibb - pressemeddelelser</title>
    <link>https://www.mynewsdesk.com/dk/bms/pressreleases</link>
    <description>Mynewsdesk nyhedsfeed direkte fra kilden</description>
    <image>
      <title>Bristol-Myers Squibb - pressemeddelelser</title>
      <link>https://www.mynewsdesk.com/dk/bms/pressreleases</link>
      <url>https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png</url>
      <width>128</width>
      <height>23</height>
    </image>
    <language>da</language>
    <ttl>15</ttl>
<item>
  <title>Bristol-Myers Squibb offentliggør resultater fra analyse af langtidsoverlevelse hos mere end 1.800 patienter.</title>
  <pubDate>Sat, 28 Sep 2013 20:20:00 +0200</pubDate>
  <description>Bristol-Myers Squibb offentliggør resultater fra analyse af langtidsoverlevelse hos mere end 
1.800 patienter behandlet med Yervoy® (Ipilimumab) mod fremskreden (inoperabel eller metastatisk) modermærkekræft</description>
  <guid>https://www.mynewsdesk.com/dk/bms/pressreleases/bristol-myers-squibb-offentliggoer-resultater-fra-analyse-af-langtidsoverlevelse-hos-mere-end-1-dot-800-patienter-930874?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>https://www.mynewsdesk.com/dk/bms/pressreleases/bristol-myers-squibb-offentliggoer-resultater-fra-analyse-af-langtidsoverlevelse-hos-mere-end-1-dot-800-patienter-930874?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Bristol-Myers Squibb</dc:creator>
</item>
  </channel>
</rss>
